[Federal Register Volume 60, Number 87 (Friday, May 5, 1995)]
[Notices]
[Pages 22401-22402]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-11118]



-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary


Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) has made final findings of scientific misconduct in the following 
case:
    Terence S. Herman, M.D., Harvard Medical School: The Division of 
Research Investigations (DRI) of the Office of Research Integrity (ORI) 
reviewed an investigation conducted by Harvard Medical School into 
possible scientific misconduct on the part of Dr. Herman while he was 
an employee of that institution. ORI concurred with the factual 
findings as set forth in the institution's report, and finds that Dr. 
Herman committed scientific misconduct by falsely reporting in a 
published article that research had been conducted according to a 
stated protocol when, in fact, Dr. Herman knew at the time that the 
protocol for tumor measurements had not been carried out exactly as 
described. The research was supported by grant awards from the National 
Cancer Institute and the National Center for Research Resources, 
National Institutes of Health. [[Page 22402]] 
    Dr. Herman accepted the misconduct finding as part of a Voluntary 
Settlement Agreement under which, for a period of three years, an 
institution which submits an application for PHS support for a clinical 
research project on which his participation is proposed or which uses 
him in any capacity on PHS supported clinical research must 
concurrently submit a plan for supervision of his duties. The 
supervisory plan must be designed to ensure the scientific integrity of 
Dr. Herman's research contribution. Dr. Herman also is prohibited from 
serving on any Public Health Service advisory committee, board, and/or 
peer review committee for a period of three years. He has agreed to 
submit a letter to the International Journal of Radiation Oncology, 
Biology, Physics requesting retraction of that portion of the article 
dealing with tumor response (Herman, et al., A Phase I-II Trial of 
Cisplatin, Hyperthermia and Radiation in patients with Locally Advanced 
Malignancies. Int. J. Radiation Oncology Biol. Phys. 17:1273-1278; 
1989).

FOR FURTHER INFORMATION CONTACT:
Director, Division of Research Investigations, Office of Research 
Integrity, 301-443-5330.

Lyle W. Bivens,
Director, Office of Research Integrity.
[FR Doc. 95-11118 Filed 5-4-95; 8:45 am]
BILLING CODE 4160-17-M